Objective-To examine the hypothesis that tenascin, an extracellular matrix glycoprotein, contributes to fibrotic changes in dilated cardiomyopathy. Methods-The localisation of tenascin in biopsy specimens of the hearts obtained from eight patients with dilated cardiomyopathy was examined using staining by the avidin-biotin-peroxidase complex method
patients, moderately intense staining was characteristically observed near the replacement fibrotic lesions. In the narrow perimysium and endomysium of the myocardium not containing replacement fibrotic lesions, tenascin was not present, as in the control specimens. (2) Replacement fibrotic lesions. Non-homogeneous positive staining for tenascin was detected in all replacement fibrotic lesions examined. Intense tenascin deposition was observed in the peripheral portion of the replacement fibrotic lesions. The tenascin staining observed in the small replacement fibrotic lesions was more intense than that in the large lesions. Conclusions-Tenascin contributes to the development of the fibrotic changes seen in the dilated cardiomyopathic heart. Its characteristic location, specifically the distribution along the margin of the fibrosis, suggests that fibrotic change is a continuous process in hearts with dilated cardiomyopathy. Since it was impossible to obtain normal heart biopsy specimens, left ventricular specimens obtained from two necropsy cases without any heart disease served as controls.
IMMUNOHISTOCHEMISTRY
For the immunohistochemical study, we stained the frozen biopsy specimens by the avidin-biotin-peroxidase complex (ABC) method.7 Briefly, the primary antibody used in this study was rabbit anti-human tenascin polyclonal antibody (Chemicon) diluted 1:500 (2 ul/ml) with phosphate buffered saline (PBS) containing 1i5% normal goat serum. The sections of the specimens were incubated with the diluted primary antibody for 10 h at 4°C. The second antibody used in this study was goat anti-rabbit IgG serum (Funakoshi) diluted 1:1000 with PBS containing 1-5% normal goat serum. The sections were incubated with the second antibody for 2 h at room temperature, reacted with avidin-biotinperoxidase complex, and finally coloured with diaminobenzidine. For cell nucleus staining, the sections were incubated with 0 1 M veronal acetate buffered 1% methyl green for 1 0 min.
IMMUNOHISTOCHEMICAL CONTROL PROCEDURE
The following procedures were performed: negative control staining with normal rabbit serum instead of primary rabbit antibody for each staining; and an immunoabsorption test using purified human tenascin antigen (Nippon Koutai Kenkyusho) to the antibody.
ANALYSIS
Since the extracellular matrix components of the heart are located in the perimysium and endomysium and in lesions where fibrosis has replaced myocyte necrosis (replacement fibrotic lesions), we analysed the localisation 
Perimysium and endomysium
Positive staining for tenascin was characteristically observed in the perimysium and endomysium (intercellular spaces) around the replacement fibrotic lesions. The staining for tenascin was detected in enlarged perimysium and endomysium in all patients except patient 1, and intense staining (grade ++ or +++) for tenascin was observed in the enlarged endomysium near the replacement fibrotic lesions ( fig 1A) . Similarly, in some specimens (from patients 2 and 4) the positive staining was observed in the non-enlarged endomysium, and these tenascin positive lesions were also located near the replacement fibrotic lesions. The staining intensity in these lesions varied from lesion to lesion. On the other hand, in the narrow perimysium and endomysium of the myocardium not containing the replacement fibrotic lesions, antibody results for tenascin confirmed that tenascin was not present, as in the control specimens. 
Replacementfibrotic lesions
In all replacement fibrotic lesions, non-hor geneous positive staining for tenascin detected ( fig 1A and 1B) . The staining inl sity in the replacement fibrotic lesions also i ied from lesion to lesion. Intense tenaw deposition (++ or +++) was observed in peripheral portion of the replacement fibr lesions (fig 1A) , but was not observed in central portion of the replacement fibri lesions. The tenascin staining seen in the sr replacement fibrotic lesions was more inte than that in the large lesions ( fig 1B) .
Discussion
The findings indicate that tenascin is gener distributed in the enlarged perimysium; endomysium near the replacement fibri lesions close to necrotising myocytes an( also distributed in the peripheral portion of replacement fibrotic lesions. These findings suggest that tenascin is present in active fibrotic lesions and plays a role in the initiation of fibrotic changes that are observed in hearts with dilated cardiomyopathy.
Tenascin was found distributed in both the enlarged perimysium and endomysium of the fibrotic lesions, which are considered to have replaced the necrosed myocytes. Tenascin is an extracellular matrix glycoprotein consisting of six disulphide linked subunits with molecular masses of 190-250 kDa.9 The cDNA of human tenascin has been cloned and its amino acid sequence determined.10 Tenascin is expressed during development by several tissues. 5 11-16 These biological studies indicate that tenascin promotes the early phase of ECM formation, especially through cell migration. The present results for the characteristic location of tenascin in dilated cardiomyopathy indicate that tenascin contributes to the fibrotic process in the early phase of initiation of cell migration in the fibrotic lesion, containing necrosed myocytes.
A recent study17 showed that in the wound healing process tenascin was first detected in the stroma later than fibronectin but disappeared earlier than fibronectin. Tenascin has been reported to be abundant in healing wounds but absent in old scars18; it is detected during the early phase of wound healing but is almost completely absent by the late stage. 4 In the gastric mucosa, tenascin appears in the erosive mucosa but disappears after reepithelisation.6 Tenascin, with its chemoattractive effects, thus plays an important role in the initial wound healing process. This evidence indicates that the abundant tenascin staining observed in the extracellular matrix of the heart reflects active turnover, and that is absent or diminished tenascin staining could ade indicate the presence of mature fibrotic lesions. The results of recent studies of tenascin and the present results indicate that fibrotic changes occur continuously in the is heart with dilated cardiomyopathy. Tenascin is detected in fetal skin wounds earlier than in adult skin wounds and the wound healing occurs more rapidly in the fetus.1920 Tenascin appeared before keratinomo-cyte and fibroblast migration, and its early was appearance in the fetal wounds, through its ten-initiation of cell migration, may underlie the var-rapid epithelialisation seen in fetal wound scin healing. These studies generally indicate that the fibroblasts infiltrate the lesions in which otic tenascin is abundant. In the biopsy specimens the in the present study, staining for cell nucleus otic revealed that several fibroblasts were present nall at sites positively stained for tenascin. These nse results are consistent with reported findings.
In this study we could not clarify whether or not tenascin expression is specific for hearts with dilated cardiomyopathy. The tenascin expression was associated strongly with the -ally presence of a replacement fibrotic lesion. This and suggests that tenascin contributes to the otic fibrotic process of healing following myocyte d is damage. The same contribution to the healing the process has been found in wound healing,45 '7 gastric mucosal injury,6 and liver injury.21 It is possible that tenascin may also be expressed in the fibrotic process following myocardial damage in other pathological conditions, such as ischaemic myocardial damage.
The small number of biopsy samples we examined is a limitation of this study, as is the failure to evaluate the relationship of tenascin staining to haemodynamic indices.
In summary, our results suggest that tenascin contributes to the fibrotic changes observed in the heart in dilated cardiomyopathy. Its variable distribution is thought to indicate that the phase of the fibrotic process differs from lesion to lesion.
